恒瑞医药：HRS-4729注射液临床试验获批

Core Viewpoint - The company received approval from the National Medical Products Administration for the clinical trial of HRS-4729 injection, a self-developed peptide drug targeting multiple receptors for better weight loss and liver fat reduction [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances energy expenditure and lipid metabolism [1] - The drug aims to improve weight loss and reduce liver fat more effectively compared to dual-target GLP-1R/GIPR agonists [1] Group 2: Clinical Trial - The clinical trial for HRS-4729 injection will commence shortly following the approval [1]